Miconazole administered systemically is known to inhibit CYP3A4/2C9. Due to the limited systemic availability after topical application (see Pharmacology: Pharmacokinetics under Actions), clinically relevant interactions occur very rarely. In patients on warfarin, caution should be exercised and the anticoagulant effect should be monitored. The effects and side effects of some other drugs (e.g., oral hypoglycemic and phenytoin), when co-administered with miconazole, can be increased and caution should be exercised.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
